Based on our experiments, we find that various treatments, especially Fingolimod, induce the expression of inhibitory checkpoints, CTLA-4 and PD-L1, and increased expression or function of these molecules can result in the decreased responses of autoreactive T cells and lead to the inhibition of autoimmune diseases, including MS. The gene discussed is CTLA4; the disease is autoimmune disease.